Carboplatin Injection · 203 days since initial FDA posting
Brand: CARBOPLATIN
FDA lists Carboplatin Injection as To Be Discontinued (Ingenus Pharmaceuticals LLC).
No availability text on this FDA row.
Carboplatin Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Carboplatin Injection
- Manufacturer
- Ingenus Pharmaceuticals LLC
- Dosage Form
- Injection
- Presentation
- Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)
- Package NDC
- 50742-447-45
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Feb 20, 2026
- Last Updated
- Feb 20, 2026
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Carboplatin Shortage Records
Carboplatin Injection
Gland Pharma Limited
Injection
Carboplatin Injection
Gland Pharma Limited
Injection
Carboplatin Injection
Gland Pharma Limited
Injection
Carboplatin Injection
Gland Pharma Limited
Injection
Carboplatin Injection
Teyro Labs
Injection
Carboplatin Injection
Teyro Labs
Injection
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.